Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,136Revenue $M75.3Net Margin (%)-90.8Z-Score6.1
Enterprise Value $M2,050EPS $-0.6Operating Margin %-83.7F-Score4
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-90.8Higher ROA y-yN
Price/Book51.010-y EBITDA Growth Rate %7.3Quick Ratio6.4Cash flow > EarningsY
Price/Sales27.55-y EBITDA Growth Rate %0.7Current Ratio6.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-42.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-186.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M127ROI % (ttm)-92.5Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HALOJean-Marie Eveillard 2014-09-30 Add0.02%$8.67 - $10.2
($9.52)
$ 16.8644%Add 30.25%3,640,480
HALOJean-Marie Eveillard 2014-06-30 Add0.03%$7.09 - $12.31
($8.46)
$ 16.8650%Add 94.94%2,795,080
HALOKen Fisher 2014-06-30 Buy 0.02%$7.09 - $12.31
($8.46)
$ 16.8650%New holding791,760
HALOJean-Marie Eveillard 2013-12-31 Buy 0.05%$9.66 - $15.7
($12.86)
$ 16.8624%New holding1,294,580
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
($8.21)
$ 16.8651%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
($6.61)
$ 16.8661%New holding17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.339.98view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.9289.01view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.989.44view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.9669.28view
Engler RobertDirector 2014-08-14Sell35,000$9.9669.28view
Engler RobertDirector 2014-05-15Sell126,700$7.56123.02view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.1384.67view
Shepard H. MichaelVP, Chief Scientific Officer 2013-08-19Sell10,000$7.11137.13view
FALBERG KATHRYN EDirector 2013-08-14Buy100,000$6.82147.21view
Engler RobertDirector 2012-11-29Buy15,000$5.57202.69view

Press Releases about HALO :

    Quarterly/Annual Reports about HALO:

      News about HALO:

      Articles On GuruFocus.com
      Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
      comment on HALO May 12 2013 
      comment on HALO May 12 2013 
      comment on HALO May 12 2013 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
      Halozyme Therapeutics Reports Second Quarter 2009 Financial Results Aug 07 2009 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 
      Halozyme to Host Conference Call and Webcast on August 7 to Discuss Second Quarter 2009 Financial Re Jul 31 2009 

      More From Our Partners
      Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog Apr 9 2015 - ZACKS

      More From Other Websites
      How QVT Financial Gained from Lumber Liquidators Holdings Inc (LL)’s 53% Drop in Q1 Apr 23 2015
      Average angel investor round rises sharply Apr 22 2015
      Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual... Apr 20 2015
      Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual... Apr 20 2015
      Halozyme Therapeutics Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel... Apr 13 2015
      Halozyme Therapeutics Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel... Apr 13 2015
      Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog Apr 09 2015
      Halozyme Therapeutics Spikes Up Following FDA News Apr 08 2015
      Halozyme Provides Update Following Type B FDA Meeting Apr 08 2015
      Halozyme Provides Update Following Type B FDA Meeting Apr 08 2015
      Halozyme Therapeutics Appoints James Mazzola To Lead Corporate Communications, Investor Relations Mar 23 2015
      Halozyme Therapeutics Appoints James Mazzola To Lead Corporate Communications, Investor Relations Mar 23 2015
      Matthew Posard Joins Trovagene's Executive Management Team as Chief Commercial Officer Mar 18 2015
      How one bull is playing Halozyme Mar 18 2015
      Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration Mar 10 2015
      Halozyme Therapeutics Reports Selection Of First Product Candidate Under Janssen Collaboration Mar 10 2015
      Three Reasons to Fear Biotech Stocks Right Now Mar 09 2015
      HALOZYME THERAPEUTICS INC Financials Mar 07 2015
      10-K for Halozyme Therapeutics, Inc. Mar 04 2015
      Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference Mar 03 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK